Applied Filters
Indivior appeal fails to stop generic opioid addiction challenge
The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
German Court rules Sanofi’s Praluent infringes Amgen patent
A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.
Reckitt Benckiser to pay $1.4bn over opioid treatment sales
Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.
Genentech and Samsung Bioepis settle patent dispute over cancer biosimilar
US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.
UKIPO seeks no-deal Brexit SPC comments
The UK Intellectual Property Office has today, July 5, opened a consultation into supplementary protection certificate law in the event of a ‘no deal’ Brexit.
SPC generics waiver comes into force
The controversial supplementary protection certificate manufacturing waiver has come into force today, July 1.
Novartis secures injunction barring generic MS drugs
A US court has issued an injunction barring the manufacture of generic versions of Swiss pharmaceutical company Novartis’ multiple sclerosis drug Gileyna.
Teva infringed UCB patent, rules Fed Circuit
The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro, a patch to treat Parkinson’s disease.
Fed Circuit sides with Merck in antifungal treatment dispute
A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.
Generic drugs cost 30x more in poor countries: report
Generic medicines can cost up to 30 times more in poor countries, according to a new study.
